Clinical Trials
84
Trial Phases
5 Phases
Drug Approvals
84
Drug Approvals
Lansoprazole Enteric Capsules
- Product Name
- 兰索拉唑肠溶胶囊
- Approval Number
- 国药准字HJ20250069
- Approval Date
- Jun 10, 2025
Voriconazole for Oral Suspension
- Product Name
- 伏立康唑干混悬剂
- Approval Number
- 国药准字HJ20250023
- Approval Date
- Mar 4, 2025
Dabigatran Etexilate Capsules
- Product Name
- 达比加群酯胶囊
- Approval Number
- 国药准字HJ20240155
- Approval Date
- Dec 1, 2024
Posaconazole Enteric-coated Tablets
- Product Name
- 泊沙康唑肠溶片
- Approval Number
- 国药准字HJ20240139
- Approval Date
- Dec 1, 2024
Dabigatran Etexilate Capsules
- Product Name
- 达比加群酯胶囊
- Approval Number
- 国药准字HJ20240154
- Approval Date
- Dec 1, 2024
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (78 trials with phase data)• Click on a phase to view related trials
News
Catalyst Pharmaceuticals Secures Patent Protection for FIRDAPSE Until 2035 Through Lupin Settlement
Catalyst Pharmaceuticals and SERB S.A. reached a settlement agreement with Lupin that prevents generic competition for FIRDAPSE (amifampridine) until February 25, 2035.
Catalyst Pharmaceuticals Secures Patent Settlement with Teva, Extending Firdapse Market Exclusivity Until 2035
Catalyst Pharmaceuticals and its licensor SERB S.A. reached a settlement agreement with Teva Pharmaceuticals that prevents Teva from marketing a generic version of Firdapse until February 25, 2035.
Sputnik V COVID-19 Vaccine to be Produced in India with Hetero Collaboration
The Russian Direct Investment Fund (RDIF) and Hetero have agreed to produce over 100 million doses per year of the Sputnik V vaccine in India.
Dr. Reddy's and Hetero Partner with Gilead to Produce Generic HIV Drug Lenacapavir
• Dr. Reddy's and Hetero have signed non-exclusive licensing agreements with Gilead to manufacture and market generic lenacapavir in 120 countries. • Lenacapavir, marketed as Sunlenca, is approved for multi-drug resistant HIV-1 and is under investigation for HIV prevention (PrEP). • The agreement allows Dr. Reddy's to handle technology transfer, clinical studies, and product launches in the specified markets. • This collaboration aims to provide affordable access to lenacapavir in low- and middle-income countries with high HIV prevalence.